| Literature DB >> 33173015 |
Tianyi Gao1, Xiangxiang Liu2, Bangshun He2, Yuqin Pan2, Shukui Wang1,2,3.
Abstract
Cancer stem cells (CSCs) are believed to be the driving force behind the tumor growth. We performed this study to further explore the role of IGF2 epigenetic on CRC stem cells pluripotency which showed that IGF2 LOI CRC cells usually had a higher CD133 expression and sphere forming efficiency than MOI cells. IGF2 LOI CSCs were also found to have a higher level of autophagy than MOI CSCs. Moreover, IGF2/IR-A signal was determined to play a more important role in CSCs formation than IGF2/IGF1R. At last, by using miRNA-195 mimics, we fortunately found the increased IR-A expression might be due to the degradation of miRNA-195 in CRC. In conclusion, our results might reveal that IGF2 LOI could promote CRC stem cells pluripotency by promoting CSCs autophagy. For the degradation of miRNA-195, IGF2 showed a higher ability in interacting with overexpressed IR-A rather than IGF1R which would further activate CSCs autophagy. All these findings might provide a novel mechanistic insight into CRC diagnosis and therapy.Entities:
Keywords: CRC; CSCs pluripotency; IGF2 LOI; autophagy
Mesh:
Substances:
Year: 2020 PMID: 33173015 PMCID: PMC7695407 DOI: 10.18632/aging.103837
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1The association between IGF2 LOI and CSCs characteristics. (A) the correlation between IGF2 LOI and CD133 expression; (B) the mRNA expression of CSCs related genes in IGF2 LOI and MOI CRC cells; (C) the sphere formation assay in IGF2 LOI and MOI CSCs. After 7 days, IGF2 KD cells showed lower sphere formation efficiency than negative control or blank group (cells without any treatment) in IGF2 LOI CSCs(p<0.05). IGF2 OE cells showed higher sphere formation efficiency than negative control or blank group(p<0.05). Sphere forming efficiency = number of actual spheres/number of cells plated×100.
Figure 2The affection of IGF2 LOI in CSCs autophagy. (A) the IF results of CD133 and p62 in IGF2 LOI cells (Caco2 and HT-29) and MOI cells (Hct-8 and Hct-116); (B) the IF results of p62 in Caco2 or HT-29 CD133+cells and CD133- cells. CD133+ cells showed a lower p62 expression than CD133- cells; (C) the green-puncta and red-puncta numbers of CSCs cells in mRFP-eGFP-LC3fluorescence assay. After hunger for 6 hours, IGF2 LOI CSCs showed higher numbers of green and red LC3 dots per cell than IGF2 MOI cells(p<0.05); (D) the p62 and LC3-II expression in IGF2 LOI and MOI CSCs with different treatment; (E) the apoptosis rates of IGF2 LOI and MOI CSCs with different treatment; (F) the sphere formation efficiency and IGF2 mRNA expression of IGF2 LOI CSCs treated with 3-MA.
Figure 3The potential mechanism of IGF2 in CSCs regulation. (A) the expression levels of potential regulators downstream of IGF2. (B) the CO-IP results of IGF2 LOI CSCs with IGF2/IR-A/IGF1R antibodies; (C) the IR-A and IGF1R mRNA expression in TCGA and CRC patients; (D) the sphere formation efficiency of IGF2 LOI CSCs transfected with IR-A or IGF1R siRNA; (E) the changing of Akt, GSK3β expression in IGF2 LOI CSCs transfected with IR-A or IGF1R siRNA; (F) Typical pictures and dates of nude mice with tumorigenicity and tumors which were under different treatments.
Figure 4The regulation of miRNAs on IR-A expression. (A) the IR-A and IGF1R protein and mRNA expression in CRC and normal cells; (B) the expression levels of miRNA-195 and miRNA-15b in CRC patients; (C) the IR-A expression of IGF2 LOI CRC cells transfected with miRNA-195 mimics.